Chris Molloy to address UK’s role in global drug development at Drug Discovery Innovators & Investors Conference
Chris Molloy, Chief Executive Officer of the UK BioIndustry Association (BIA), will explore the UK’s role in the changing global drug R&D landscape in his keynote address at the Drug Discovery Innovators & Investors (DDII) UK Conference on 4 November 2026 at etc.venues Monument, London, UK.
With global drug R&D undergoing significant change, Molloy will examine why the UK is well positioned to act as an essential enabler in the evolving landscape. He will highlight the country’s public and private capital, long-term infrastructure, trusted discovery research, strong regulatory environment and expertise in areas including oncology, cell and gene therapy and rare diseases.
His keynote will also consider the priorities for the UK as it adapts to the changing landscape, including building deeper pools of capital, increasing adoption and strengthening international R&D diplomacy.
Looking further ahead, Molloy will discuss the opportunity for the UK to establish itself as a high-value trading nation in medicines R&D and play an essential role in the global drug discovery and development ecosystem over the next 50 years.
Chris Molloy’s keynote takes place at 14:45 on the conference day. Several new speakers and programme updates have also been confirmed this week, with the agenda continuing to take shape across technology, R&D, investment and drug discovery.
Early bird registration closes 16 October.
